{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T11:29:16Z","timestamp":1793878156283,"version":"4.7.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["407958\/2022-3"],"award-info":[{"award-number":["407958\/2022-3"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004901","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de Minas Gerais","doi-asserted-by":"publisher","award":["RED-00118-23"],"award-info":[{"award-number":["RED-00118-23"]}],"id":[{"id":"10.13039\/501100004901","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior (CAPES) and The Instituto Nacional de Ci\u00eancia e Tecnologia de Vacinas (INCTV).","id":[{"id":"https:\/\/ror.org\/00x0ma614","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"DOI":"10.1186\/s12951-025-03201-8","type":"journal-article","created":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T13:49:03Z","timestamp":1742305743000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["The immunogenic potential of an optimized mRNA lipid nanoparticle formulation carrying sequences from virus and protozoan antigens"],"prefix":"10.1186","volume":"23","author":[{"given":"Renata S.","family":"Fernandes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"de Assis Burle-Caldas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah Aparecida Rodrigues","family":"Sergio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Fl\u00e1via","family":"Br\u00e1z","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nath\u00e1lia Pereira","family":"da Silva Leite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milton","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"de Oliveira Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nat\u00e1lia Satchiko","family":"Hojo-Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"de Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Paula S. Moura","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fl\u00e1vio Guimar\u00e3es","family":"da Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo Tostes","family":"Gazzinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"dos Santos Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santuza M. Ribeiro","family":"Teixeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,18]]},"reference":[{"issue":"6669","key":"3201_CR1","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/35888","volume":"391","author":"A Fire","year":"1998","unstructured":"Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998;391(6669):806\u201311.","journal-title":"Nature"},{"key":"3201_CR2","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.copbio.2021.09.016","volume":"73","author":"E Kon","year":"2022","unstructured":"Kon E, Elia U, Peer D. Principles for designing an optimal mRNA lipid nanoparticle vaccine. Curr Opin Biotechnol. 2022;73:329\u201336.","journal-title":"Curr Opin Biotechnol"},{"key":"3201_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.omtn.2019.01.013","volume":"15","author":"KJ Hassett","year":"2019","unstructured":"Hassett KJ, Benenato KE, Jacquinet E, Lee A, Woods A, Yuzhakov O, Himansu S, DeterLing J, Geilich BM, Ketova T, Mihai C, Lynn A, McFadyen I, Moore MJ, Senn JJ, Stanton MG, Almarsson O, Ciaramella G, Brito LA. Optimization of lipid nanoparticles for intramuscular administration of mrna vaccines. Mol Ther Nucleic Acids. 2019;15:1\u201311.","journal-title":"Mol Ther Nucleic Acids"},{"key":"3201_CR4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41541-020-0159-8","volume":"5","author":"NAC Jackson","year":"2020","unstructured":"Jackson NAC, Kester KE, Casimiro D, Gurunathan S, DeRosa F. The promise of mRNA vaccines: a biotech and industrial perspective. NPJ Vaccines. 2020;5:11.","journal-title":"NPJ Vaccines"},{"key":"3201_CR5","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.actbio.2021.06.023","volume":"131","author":"EH Pilkington","year":"2021","unstructured":"Pilkington EH, Suys EJA, Trevaskis NL, Wheatley AK, Zukancic D, Algarni A, Al-Wassiti H, Davis TP, Pouton CW, Kent SJ, Truong NP. From influenza to COVID-19: lipid nanoparticle mRNA vaccines at the frontiers of infectious diseases. Acta Biomater. 2021;131:16\u201340.","journal-title":"Acta Biomater"},{"issue":"2","key":"3201_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.28572","volume":"95","author":"P Rzymski","year":"2023","unstructured":"Rzymski P, Szuster-Ciesielska A, Dzieciatkowski T, Gwenzi W, Fal A. mRNA vaccines: the future of prevention of viral infections? J Med Virol. 2023;95(2): e28572.","journal-title":"J Med Virol"},{"issue":"2","key":"3201_CR7","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","volume":"23","author":"K Kariko","year":"2005","unstructured":"Kariko K, Buckstein M, Ni H, Weissman D. Suppression of RNA recognition by toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity. 2005;23(2):165\u201375.","journal-title":"Immunity"},{"issue":"4","key":"3201_CR8","first-page":"491","volume":"17","author":"M Karam","year":"2022","unstructured":"Karam M, Daoud G. mRNA vaccines: past, present, future. Asian J Pharm Sci. 2022;17(4):491\u2013522.","journal-title":"Asian J Pharm Sci"},{"key":"3201_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s13273-021-00171-4","volume":"18","author":"SC Kim","year":"2022","unstructured":"Kim SC, Sekhon SS, Shin WR, Ahn G, Cho BK, Ahn JY, Kim YH. Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency. Mol Cell Toxicol. 2022;18:1\u20138.","journal-title":"Mol Cell Toxicol"},{"issue":"4","key":"3201_CR10","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrd.2017.243","volume":"17","author":"N Pardi","year":"2018","unstructured":"Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines. a new era in vaccinology. Nat Rev Drug Discov. 2018;17(4):261\u201379.","journal-title":"Nat Rev Drug Discov"},{"issue":"12","key":"3201_CR11","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","volume":"6","author":"X Hou","year":"2021","unstructured":"Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nat Rev Mater. 2021;6(12):1078\u201394.","journal-title":"Nat Rev Mater"},{"key":"3201_CR12","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.jconrel.2015.08.007","volume":"217","author":"N Pardi","year":"2015","unstructured":"Pardi N, Tuyishime S, Muramatsu H, Kariko K, Mui BL, Tam YK, Madden TD, Hope MJ, Weissman D. Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes. J Control Release. 2015;217:345\u201351.","journal-title":"J Control Release"},{"key":"3201_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2021.120586","volume":"601","author":"L Schoenmaker","year":"2021","unstructured":"Schoenmaker L, Witzigmann D, Kulkarni JA, Verbeke R, Kersten G, Jiskoot W, Crommelin DJA. mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability. Int J Pharm. 2021;601: 120586.","journal-title":"Int J Pharm"},{"issue":"12","key":"3201_CR14","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1016\/j.ymthe.2017.08.006","volume":"25","author":"F Liang","year":"2017","unstructured":"Liang F, Lindgren G, Lin A, Thompson EA, Ols S, Rohss J, John S, Hassett K, Yuzhakov O, Bahl K, Brito LA, Salter H, Ciaramella G, Lore K. Efficient targeting and activation of antigen-presenting cells In Vivo after modified mRNA vaccine administration in rhesus macaques. Mol Ther. 2017;25(12):2635\u201347.","journal-title":"Mol Ther"},{"issue":"5","key":"3201_CR15","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/s41551-019-0378-3","volume":"3","author":"KE Lindsay","year":"2019","unstructured":"Lindsay KE, Bhosle SM, Zurla C, Beyersdorf J, Rogers KA, Vanover D, Xiao P, Arainga M, Shirreff LM, Pitard B, Baumhof P, VilLinger F, Santangelo PJ. Visualization of early events in mRNA vaccine delivery in non-human primates via PET-CT and near-infrared imaging. Nat Biomed Eng. 2019;3(5):371\u201380.","journal-title":"Nat Biomed Eng"},{"issue":"3","key":"3201_CR16","doi-asserted-by":"publisher","first-page":"2700","DOI":"10.3390\/ijms24032700","volume":"24","author":"V Gote","year":"2023","unstructured":"Gote V, Bolla PK, Kommineni N, Butreddy A, Nukala PK, Palakurthi SS, Khan W. A comprehensive review of mRNA vaccines. Int J Mol Sci. 2023;24(3):2700.","journal-title":"Int J Mol Sci"},{"issue":"Pt A","key":"3201_CR17","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.addr.2016.01.022","volume":"99","author":"X Cheng","year":"2016","unstructured":"Cheng X, Lee RJ. The role of helper lipids in lipid nanoparticles (LNPs) designed for oligonucleotide delivery. Adv Drug Deliv Rev. 2016;99(Pt A):129\u201337.","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"3201_CR18","doi-asserted-by":"publisher","first-page":"7233","DOI":"10.1038\/s41467-021-27493-0","volume":"12","author":"X Han","year":"2021","unstructured":"Han X, Zhang H, Butowska K, Swingle KL, Alameh MG, Weissman D, Mitchell MJ. An ionizable lipid toolbox for RNA delivery. Nat Commun. 2021;12(1):7233.","journal-title":"Nat Commun"},{"issue":"1","key":"3201_CR19","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1021\/acs.accounts.1c00544","volume":"55","author":"Y Eygeris","year":"2022","unstructured":"Eygeris Y, Gupta M, Kim J, Sahay G. Chemistry of lipid nanoparticles for RNA delivery. Acc Chem Res. 2022;55(1):2\u201312.","journal-title":"Acc Chem Res"},{"key":"3201_CR20","doi-asserted-by":"publisher","first-page":"114416","DOI":"10.1016\/j.addr.2022.114416","volume":"188","author":"CH Albertsen","year":"2022","unstructured":"Albertsen CH, Kulkarni JA, Witzigmann D, Lind M, Petersson K, Simonsen JB. The role of lipid components in lipid nanoparticles for vaccines and gene therapy. Adv Drug Deliv Rev. 2022;188:114416.","journal-title":"Adv Drug Deliv Rev"},{"issue":"11","key":"3201_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0187962","volume":"12","author":"M Maeki","year":"2017","unstructured":"Maeki M, Fujishima Y, Sato Y, Yasui T, Kaji N, Ishida A, Tani H, Baba Y, Harashima H, Tokeshi M. Understanding the formation mechanism of lipid nanoparticles in microfluidic devices with chaotic micromixers. PLoS ONE. 2017;12(11): e0187962.","journal-title":"PLoS ONE"},{"key":"3201_CR22","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.jconrel.2022.02.017","volume":"344","author":"M Maeki","year":"2022","unstructured":"Maeki M, Uno S, Niwa A, Okada Y, Tokeshi M. Microfluidic technologies and devices for lipid nanoparticle-based RNA delivery. J Control Release. 2022;344:80\u201396.","journal-title":"J Control Release"},{"key":"3201_CR23","doi-asserted-by":"publisher","first-page":"1700375","DOI":"10.1002\/smtd.201700375","volume":"2","author":"MJW Evers","year":"2018","unstructured":"Evers MJW, Kulkarni JA, van der Meel R, Cullis PR, Vader P, Schiffelers RM. State-of-the-art design and rapid-mixing production techniques of lipid nanoparticles for nucleic acid delivery. Small Methods. 2018;2:1700375.","journal-title":"Small Methods"},{"issue":"11","key":"3201_CR24","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1016\/j.immuni.2022.10.014","volume":"55","author":"R Verbeke","year":"2022","unstructured":"Verbeke R, Hogan MJ, Lore K, Pardi N. Innate immune mechanisms of mRNA vaccines. Immunity. 2022;55(11):1993\u20132005.","journal-title":"Immunity"},{"issue":"5","key":"3201_CR25","doi-asserted-by":"publisher","first-page":"319","DOI":"10.4155\/tde-2016-0006","volume":"7","author":"AM Reichmuth","year":"2016","unstructured":"Reichmuth AM, Oberli MA, Jaklenec A, Langer R, Blankschtein D. mRNA vaccine delivery using lipid nanoparticles. Ther Deliv. 2016;7(5):319\u201334.","journal-title":"Ther Deliv"},{"key":"3201_CR26","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jconrel.2021.05.021","volume":"335","author":"KJ Hassett","year":"2021","unstructured":"Hassett KJ, Higgins J, Woods A, Levy B, Xia Y, Hsiao CJ, Acosta E, Almarsson O, Moore MJ, Brito LA. Impact of lipid nanoparticle size on mRNA vaccine immunogenicity. J Control Release. 2021;335:237\u201346.","journal-title":"J Control Release"},{"issue":"8","key":"3201_CR27","doi-asserted-by":"publisher","first-page":"2867","DOI":"10.1021\/acs.molpharmaceut.1c00447","volume":"18","author":"D Chatzikleanthous","year":"2021","unstructured":"Chatzikleanthous D, O\u2019Hagan DT, Adamo R. Lipid-based nanoparticles for delivery of vaccine adjuvants and antigens: toward multicomponent vaccines. Mol Pharm. 2021;18(8):2867\u201388.","journal-title":"Mol Pharm"},{"issue":"39","key":"3201_CR28","doi-asserted-by":"publisher","first-page":"eaaw7083","DOI":"10.1126\/sciimmunol.aaw7083","volume":"4","author":"S Awasthi","year":"2019","unstructured":"Awasthi S, Hook LM, Pardi N, Wang F, Myles A, Cancro MP, Cohen GH, Weissman D, Friedman HM. Nucleoside-modified mRNA encoding HSV-2 glycoproteins C, D, and E prevents cLinical and subcLinical genital herpes. Sci Immunol. 2019;4(39):eaaw7083.","journal-title":"Sci Immunol"},{"issue":"3","key":"3201_CR29","doi-asserted-by":"publisher","first-page":"433","DOI":"10.3390\/vaccines8030433","volume":"8","author":"S Shirai","year":"2020","unstructured":"Shirai S, Kawai A, Shibuya M, Munakata L, Omata D, Suzuki R, Yoshioka Y. Lipid nanoparticle acts as a potential adjuvant for influenza split vaccine without inducing inflammatory responses. Vaccines. 2020;8(3):433.","journal-title":"Vaccines"},{"key":"3201_CR30","first-page":"532","volume":"4","author":"S Tahtinen","year":"2020","unstructured":"Tahtinen S, Tong AJ, Himmels P, Oh J, Paler-Martinez A, Kim L, Wichner S, Oei Y, McCarron MJ, Freund EC, Amir ZA, de la Cruz CC, Haley B, Blanchette C, Schartner JM, Ye W, Yadav M, Sahin U, Delamarre L, Mellman I. IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines. Nat Immunol. 2020;4:532\u201342.","journal-title":"Nat Immunol"},{"issue":"12","key":"3201_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2021.103479","volume":"24","author":"S Ndeupen","year":"2021","unstructured":"Ndeupen S, Qin Z, Jacobsen S, Bouteau A, Estanbouli H, Igy\u00e1rt\u00f3 BZ. The mRNA-LNP platform\u2019s lipid nanoparticle component used in precLinical vaccine studies is highly inflammatory. IScience. 2021;24(12): 103479.","journal-title":"IScience"},{"issue":"12","key":"3201_CR32","doi-asserted-by":"publisher","first-page":"2877","DOI":"10.1016\/j.immuni.2021.11.001","volume":"54","author":"MG Alameh","year":"2021","unstructured":"Alameh MG, Tombacz I, Bettini E, Lederer K, Sittplangkoon C, Wilmore JR, Gaudette BT, Soliman OY, Pine M, Hicks P, Manzoni TB, Knox JJ, Johnson JL, Laczko D, Muramatsu H, Davis B, Meng W, Rosenfeld AM, Strohmeier S, Lin PJC, Mui BL, Tam YK, Kariko K, Jacquet A, Krammer F, Bates P, Cancro MP, Weissman D, Luning Prak ET, Allman D, Locci M, Pardi N. Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses. Immunity. 2021;54(12):2877\u201328922877.","journal-title":"Immunity"},{"issue":"7","key":"3201_CR33","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.3390\/pharmaceutics15071972","volume":"15","author":"N Al Fayez","year":"2023","unstructured":"Al Fayez N, Nassar MS, Alshehri AA, Alnefaie MK, Almughem FA, Alshehri BY, Alawad AO, Tawfik EA. Recent advancement in mRNA vaccine development and applications. Pharmaceutics. 2023;15(7):1972.","journal-title":"Pharmaceutics"},{"key":"3201_CR34","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/s41541-023-00751-6","volume":"8","author":"L Zhang","year":"2023","unstructured":"Zhang L, More KR, Ojha A, Jackson CB, Quinlan BD, Li H, He W, Farzan M, Pardi N, Choe H. Effect of mRNA-LNP components of two globally-marketed COVID-19 vaccines on efficacy and stability. NPJ Vaccines. 2023;8:156.","journal-title":"NPJ Vaccines"},{"issue":"1","key":"3201_CR35","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s11095-022-03460-2","volume":"40","author":"D Sun","year":"2023","unstructured":"Sun D, Lu ZR. Structure and function of cationic and ionizable lipids for nucleic acid delivery. Pharm Res. 2023;40(1):27\u201346.","journal-title":"Pharm Res"},{"issue":"1","key":"3201_CR36","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1038\/s42003-021-02441-2","volume":"4","author":"MJ Carrasco","year":"2021","unstructured":"Carrasco MJ, Alishetty S, Alameh MG, Said H, Wright L, Paige M, Soliman O, Weissman D, Cleveland TE 4th, Grishaev A, Buschmann MD. Ionization and structural properties of mRNA lipid nanoparticles influence expression in intramuscular and intravascular administration. Commun Biol. 2021;4(1):956.","journal-title":"Commun Biol"},{"issue":"7","key":"3201_CR37","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1021\/acs.jpcb.7b10795","volume":"122","author":"J Viger-Gravel","year":"2018","unstructured":"Viger-Gravel J, Schantz A, Pinon AC, Rossini AJ, Schantz S, Emsley L. Structure of lipid nanoparticles containing siRNA or mRNA by dynamic nuclear polarization-enhanced NMR spectroscopy. J Phys Chem B. 2018;122(7):2073\u201381.","journal-title":"J Phys Chem B"},{"issue":"14","key":"3201_CR38","doi-asserted-by":"publisher","first-page":"2766","DOI":"10.1016\/j.bpj.2021.03.012","volume":"120","author":"ML Brader","year":"2021","unstructured":"Brader ML, Williams SJ, Banks JM, Hui WH, Zhou ZH, Jin L. Encapsulation state of messenger RNA inside lipid nanoparticles. Biophys J. 2021;120(14):2766\u201370.","journal-title":"Biophys J"},{"issue":"2","key":"3201_CR39","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1039\/D1BM01454D","volume":"10","author":"E Alvarez-Benedicto","year":"2022","unstructured":"Alvarez-Benedicto E, Farbiak L, Marquez Ramirez M, Wang X, Johnson LT, Mian O, Guerrero ED, Siegwart DJ. Optimization of phospholipid chemistry for improved lipid nanoparticle (LNP) delivery of messenger RNA (mRNA). Biomater Sci. 2022;10(2):549\u201359.","journal-title":"Biomater Sci"},{"key":"3201_CR40","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.202110137","author":"P Paramasivam","year":"2022","unstructured":"Paramasivam P, Franke C, Stoter M, Hoijer A, Bartesaghi S, Sabirsh A, Lindfors L, Arteta MY, Dahlen A, Bak A, Andersson S, Kalaidzidis Y, Bickle M, Zerial M. Endosomal escape of delivered mRNA from endosomal recycling tubules visualized at the nanoscale. J Cell Biol. 2022. https:\/\/doi.org\/10.1083\/jcb.202110137.","journal-title":"J Cell Biol"},{"issue":"6","key":"3201_CR41","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1016\/j.ymthe.2017.03.035","volume":"25","author":"K Bahl","year":"2017","unstructured":"Bahl K, Senn JJ, Yuzhakov O, Bulychev A, Brito LA, Hassett KJ, Laska ME, Smith M, Almarsson O, Thompson J, Ribeiro AM, Watson M, Zaks T, Ciaramella G. Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses. Mol Ther. 2017;25(6):1316\u201327.","journal-title":"Mol Ther"},{"issue":"5","key":"3201_CR42","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.cell.2020.07.024","volume":"182","author":"NN Zhang","year":"2020","unstructured":"Zhang NN, Li XF, Deng YQ, Zhao H, Huang YJ, Yang G, Huang WJ, Gao P, Zhou C, Zhang RR, Guo Y, Sun SH, Fan H, Zu SL, Chen Q, He Q, Cao TS, et al. A Thermostable mRNA Vaccine against COVID-19. Cell. 2020;182(5):1271-1283 e1216.","journal-title":"Cell"},{"issue":"6","key":"3201_CR43","doi-asserted-by":"publisher","first-page":"9627","DOI":"10.1021\/acsnano.0c10180","volume":"15","author":"U Elia","year":"2021","unstructured":"Elia U, Ramishetti S, Rosenfeld R, Dammes N, Bar-Haim E, Naidu GE, Makdasi E, Yahalom-Ronen Y, Tamir H, Paran N, Cohen O, Peer D. Design of SARS-CoV-2 hFc-conjugated receptor-binding domain mRNA vaccine delivered via lipid nanoparticles. ACS Nano. 2021;15(6):9627\u201337.","journal-title":"ACS Nano"},{"key":"3201_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2022.114238","volume":"185","author":"W Ngo","year":"2022","unstructured":"Ngo W, Ahmed S, Blackadar C, Bussin B, Ji Q, Mladjenovic SM, Sepahi Z, Chan WCW. Why nanoparticles prefer liver macrophage cell uptake in vivo. Adv Drug Deliv Rev. 2022;185: 114238.","journal-title":"Adv Drug Deliv Rev"},{"issue":"12","key":"3201_CR45","doi-asserted-by":"publisher","first-page":"e02482","DOI":"10.1128\/JVI.02482-20","volume":"95","author":"CJ Wollner","year":"2021","unstructured":"Wollner CJ, Richner M, Hassert MA, Pinto AK, Brien JD, Richner JM. A dengue virus serotype 1 mRNA-LNP vaccine elicits protective immune responses. J Virol. 2021;95(12):e02482-e2520.","journal-title":"J Virol"},{"issue":"11","key":"3201_CR46","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.3390\/pathogens11111259","volume":"11","author":"MS Duthie","year":"2022","unstructured":"Duthie MS, Machado BAS, Badar\u00f3 R, Kaye PM, Reed SG. Leishmaniasis vaccines: applications of RNA technology and targeted clinical trial designs. Pathogens. 2022;11(11):1259.","journal-title":"Pathogens"},{"issue":"2","key":"3201_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.micinf.2021.104884","volume":"24","author":"DCO Gomes","year":"2022","unstructured":"Gomes DCO, Souza BLSC, Schwedersky RP, Covre LP, Guedes HLM, Lopes UG, R\u00e9 MI, Rossi-Bergmann B. Intranasal immunization with chitosan microparticles enhances LACK-DNA vaccine protection and induces specific long-lasting immunity against visceral leishmaniasis. Microbes Infect. 2022;24(2): 104884.","journal-title":"Microbes Infect"},{"issue":"1","key":"3201_CR48","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/imm.13007","volume":"156","author":"J He","year":"2019","unstructured":"He J, Huang F, Zhang J, Chen H, Chen Q, Zhang J, Li J, Zheng Z, Chen D, Chen J. DNA prime-protein boost vaccine encoding HLA-A2, HLA-A24 and HLA-DR1 restricted epitopes of CaNA2 against visceral leishmaniasis. Immunology. 2019;156(1):94\u2013108.","journal-title":"Immunology"},{"issue":"2","key":"3201_CR49","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.vaccine.2020.11.064","volume":"39","author":"SO Emerick","year":"2021","unstructured":"Emerick SO, de Carvalho TV, Miranda BM, da Silva AC, Martins TVF, de Oliveira LL, Marques-da-Silva EA. Lipophosphoglycan-3 protein from Leishmania infantum chagasi plus saponin adjuvant: a new promising vaccine against visceral leishmaniasis. Vaccine. 2021;39(2):282\u201391.","journal-title":"Vaccine"},{"issue":"1","key":"3201_CR50","doi-asserted-by":"publisher","first-page":"17542","DOI":"10.1038\/s41598-021-97038-4","volume":"11","author":"T Imagawa","year":"2021","unstructured":"Imagawa T, Ito M, Matsuda M, Nakashima K, Tokunaga Y, Ohta Y, Li TC, Suzuki R, Suzuki T. Virus-like particles with FLAG-tagged envelope protein as a tetravalent dengue vaccine candidate. Sci Rep. 2021;11(1):17542.","journal-title":"Sci Rep"},{"issue":"4","key":"3201_CR51","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1007\/s10989-021-10277-x","volume":"27","author":"NK Dixit","year":"2021","unstructured":"Dixit NK. Design of monovalent and chimeric tetravalent dengue vaccine using an immunoinformatics approach. Int J Pept Res Ther. 2021;27(4):2607\u201324.","journal-title":"Int J Pept Res Ther"},{"issue":"3","key":"3201_CR52","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s40259-022-00531-z","volume":"36","author":"JM Torres-Flores","year":"2022","unstructured":"Torres-Flores JM, Reyes-Sandoval A, Salazar MI. Dengue vaccines: an update. BioDrugs. 2022;36(3):325\u201336.","journal-title":"BioDrugs"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-025-03201-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-025-03201-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-025-03201-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T14:17:20Z","timestamp":1742307440000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnanobiotechnology.biomedcentral.com\/articles\/10.1186\/s12951-025-03201-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,18]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3201"],"URL":"https:\/\/doi.org\/10.1186\/s12951-025-03201-8","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,18]]},"assertion":[{"value":"17 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"221"}}